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Experimental studies support that fever after ischaemic
brain injury may not only be a surrogate marker for severe
cerebral ischaemia but may also deteriorate pre-existent
cerebral ischaemic damage and should therefore be treated
[1,2]. Neurological damage after cardiac arrest (CA) still
determines the final outcome and post-CA critical care
focuses on maximal neuroprotection, the application of
therapeutic hypothermia (TH). Since the use of TH, many
reports have been published on the occurrence of fever
post TH or so-called post-cooling fever (PCF). However,
the incidence of post-CA fever without TH is similar,
ranging from 20 to 78%, suggesting that episodes of
temperature >38°C are likely to occur in all patients after
CA irrespective of whether TH was administered.
Bro-Jeppesen and colleagues reported a higher 30-day
mortality in patients with PCF (temperature >38.5°C)
compared with patients without (36% vs. 22%) [3]. Like-
wise, 1-year unfavourable neurological outcome (43% vs.
27%) was higher in patients with PCF compared with
patients without. Maximum temperature and PCF dura-
tion were independent predictors of mortality. Their PCF
incidence (50.4%, 136/270) was high, probably explained
by a longer observation period (36 hours). Leary and col-
leagues reported a PCF incidence of 41% (69/176) within
24 hours after rewarming [4], while Gebhardt and collea-
gues reported a 42% incidence (141/336) within 48 hours
after CA [5] (both defined PCF as temperature >38°C).
Most importantly, recent data suggest that the effect on
mortality becomes significant only with PCF >39°C and
a minimum duration of 7 hours. Similarly, Leary and col-
leagues did not find any effect of PCF on survival and
neurological outcome, but a maximum temperature
>38.7°C was associated with worse outcome. A prospec-
tive analysis of our own post-CA data confirmed this
increased mortality in the presence of PCF only above
39°C. In our population of 76 out-of-hospital post-CA
patients, PCF between 38 and 39°C did not influence
outcome.
The question remains whether we should actively treat
(or even prevent) PCF. Many currently applied TH proto-
cols do include a post-cooling period (until 36 hours after
rewarming) of induced normothermia (37°C by endovas-
cular or surface cooling) [6]. But is this prolonged nor-
mothermia practice improving the (neurological) outcome
of our patient? There are arguments in favour of a correla-
tion between high PCF (above 39°C) and post-CA out-
come. However, whether this high fever is only an
epiphenomenon of the severity of cerebral ischaemic
injury and whether outcome can be improved by applica-
tion of strict normothermia in the early post-cooling
hours is still undetermined.
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